These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 16181820

  • 1. Cardioprotection: a new paradigm in the management of acute heart failure syndromes.
    Maytin M, Colucci WS.
    Am J Cardiol; 2005 Sep 19; 96(6A):26G-31G. PubMed ID: 16181820
    [Abstract] [Full Text] [Related]

  • 2. The cardioprotective effects of levosimendan: preclinical and clinical evidence.
    Pollesello P, Papp Z.
    J Cardiovasc Pharmacol; 2007 Sep 19; 50(3):257-63. PubMed ID: 17878752
    [Abstract] [Full Text] [Related]

  • 3. Levosimendan: beyond its simple inotropic effect in heart failure.
    Antoniades C, Tousoulis D, Koumallos N, Marinou K, Stefanadis C.
    Pharmacol Ther; 2007 May 19; 114(2):184-97. PubMed ID: 17363065
    [Abstract] [Full Text] [Related]

  • 4. Randomized clinical trials with levosimendan.
    Mebazaa A, Barraud D, Welschbillig S.
    Am J Cardiol; 2005 Sep 19; 96(6A):74G-9G. PubMed ID: 16181826
    [Abstract] [Full Text] [Related]

  • 5. Effects of levosimendan on the energy balance: preclinical and clinical evidence.
    Nieminen MS, Pollesello P, Vajda G, Papp Z.
    J Cardiovasc Pharmacol; 2009 Apr 19; 53(4):302-10. PubMed ID: 19276987
    [Abstract] [Full Text] [Related]

  • 6. The clinical experience with levosimendan in anesthesiology and in the intensive care unit.
    Cavana M, Pignataro C, Fraticelli A, Mebazaa A.
    Ital Heart J; 2003 May 19; 4 Suppl 2():61S-64S. PubMed ID: 14635372
    [Abstract] [Full Text] [Related]

  • 7. Pharmacology of new agents for acute heart failure syndromes.
    Gheorghiade M, Teerlink JR, Mebazaa A.
    Am J Cardiol; 2005 Sep 19; 96(6A):68G-73G. PubMed ID: 16181825
    [Abstract] [Full Text] [Related]

  • 8. Pharmacology of levosimendan: inotropic, vasodilatory and cardioprotective effects.
    Pathak A, Lebrin M, Vaccaro A, Senard JM, Despas F.
    J Clin Pharm Ther; 2013 Oct 19; 38(5):341-9. PubMed ID: 23594161
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The utility of levosimendan in the treatment of heart failure.
    Lehtonen L, Põder P.
    Ann Med; 2007 Oct 19; 39(1):2-17. PubMed ID: 17364447
    [Abstract] [Full Text] [Related]

  • 12. Levosimendan: dual mechanisms for acute heart failure...and beyond?
    Ng TM, Akhter MW.
    Minerva Cardioangiol; 2005 Dec 19; 53(6):565-84. PubMed ID: 16333239
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Novel biologic mechanisms of levosimendan and its effect on the failing heart.
    Parissis JT, Andreadou I, Bistola V, Paraskevaidis I, Filippatos G, Kremastinos DT.
    Expert Opin Investig Drugs; 2008 Aug 19; 17(8):1143-50. PubMed ID: 18616411
    [Abstract] [Full Text] [Related]

  • 16. Levosimendan: a new option in acute cardiac failure.
    Holley AD, Ziegenfuss M.
    Emerg Med Australas; 2006 Aug 19; 18(5-6):505-9. PubMed ID: 17083641
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Levosimendan: a novel inotropic agent for treatment of acute, decompensated heart failure.
    Earl GL, Fitzpatrick JT.
    Ann Pharmacother; 2005 Nov 19; 39(11):1888-96. PubMed ID: 16219899
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.